Licochalcone a inhibits the growth of colon carcinoma and attenuates cisplatin-induced toxicity without a loss of chemotherapeutic efficacy in mice

Chang Ki Lee, Seung Hwa Son, Kwang Kyun Park, Jung Han Yoon Park, Soon Sung Lim, Sook Hyang Kim, WonYoon Chung

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Although chemotherapy has an important function in the treatment of most solid tumours, its clinical applications are limited by severe side effects such as nephrotoxicity, hepatotoxicity, ototoxicity and neurotoxicity. Recently, a growing amount of attention has been focused on the investigation of the effects of chemopreventive agents on the inhibition of cancer cell growth and toxicity in combination with chemotherapeutics. The aim of this study was to determine whether licochalcone A (LCA) has the potential to serve as a beneficial supplement during cisplatin chemotherapy. We found that the administration of LCA alone significantly inhibited the size of the solid tumours in CT-26 cell-inoculated Balb/c mice, without any detectable induction of nephrotoxicity, hepatotoxicity and oxidative stress. LCA also suppressed cell proliferation by reducing DNA synthesis of CT-26 murine colon cancer cells in a dose-dependent manner. LCA did not affect the therapeutic efficacy of cisplatin. Furthermore, LCA inhibited the cisplatin-induced kidney damage characterized by increases in the serum creatinine and blood urea nitrogen, as well as the cisplatin-induced liver damage characterized by increases in the serum alanine aminotransferase and aspartate aminotransferase. The repeated oral administration of LCA prior to cisplatin treatment exerted a preventive effect on the cisplatin-mediated increases in the serum nitric oxide and the tissue lipid peroxidation levels, and recovered the depleted reduced glutathione levels in the tissues. These results suggest that supplementation with LCA may be beneficial in counteracting the side effects of cisplatin therapy in cancer patients.

Original languageEnglish
Pages (from-to)48-54
Number of pages7
JournalBasic and Clinical Pharmacology and Toxicology
Volume103
Issue number1
DOIs
Publication statusPublished - 2008 Jul 1

Fingerprint

Cisplatin
Toxicity
Colon
Carcinoma
Growth
Chemotherapy
Tumors
Neoplasms
Serum
Tissue
Drug Therapy
Oxidative stress
Blood Urea Nitrogen
Cell proliferation
Cell growth
Therapeutics
Aspartate Aminotransferases
licochalcone A
Alanine Transaminase
Liver

All Science Journal Classification (ASJC) codes

  • Toxicology
  • Pharmacology

Cite this

Lee, Chang Ki ; Son, Seung Hwa ; Park, Kwang Kyun ; Park, Jung Han Yoon ; Lim, Soon Sung ; Kim, Sook Hyang ; Chung, WonYoon. / Licochalcone a inhibits the growth of colon carcinoma and attenuates cisplatin-induced toxicity without a loss of chemotherapeutic efficacy in mice. In: Basic and Clinical Pharmacology and Toxicology. 2008 ; Vol. 103, No. 1. pp. 48-54.
@article{f83d4254710246058b616c4ea6d5779a,
title = "Licochalcone a inhibits the growth of colon carcinoma and attenuates cisplatin-induced toxicity without a loss of chemotherapeutic efficacy in mice",
abstract = "Although chemotherapy has an important function in the treatment of most solid tumours, its clinical applications are limited by severe side effects such as nephrotoxicity, hepatotoxicity, ototoxicity and neurotoxicity. Recently, a growing amount of attention has been focused on the investigation of the effects of chemopreventive agents on the inhibition of cancer cell growth and toxicity in combination with chemotherapeutics. The aim of this study was to determine whether licochalcone A (LCA) has the potential to serve as a beneficial supplement during cisplatin chemotherapy. We found that the administration of LCA alone significantly inhibited the size of the solid tumours in CT-26 cell-inoculated Balb/c mice, without any detectable induction of nephrotoxicity, hepatotoxicity and oxidative stress. LCA also suppressed cell proliferation by reducing DNA synthesis of CT-26 murine colon cancer cells in a dose-dependent manner. LCA did not affect the therapeutic efficacy of cisplatin. Furthermore, LCA inhibited the cisplatin-induced kidney damage characterized by increases in the serum creatinine and blood urea nitrogen, as well as the cisplatin-induced liver damage characterized by increases in the serum alanine aminotransferase and aspartate aminotransferase. The repeated oral administration of LCA prior to cisplatin treatment exerted a preventive effect on the cisplatin-mediated increases in the serum nitric oxide and the tissue lipid peroxidation levels, and recovered the depleted reduced glutathione levels in the tissues. These results suggest that supplementation with LCA may be beneficial in counteracting the side effects of cisplatin therapy in cancer patients.",
author = "Lee, {Chang Ki} and Son, {Seung Hwa} and Park, {Kwang Kyun} and Park, {Jung Han Yoon} and Lim, {Soon Sung} and Kim, {Sook Hyang} and WonYoon Chung",
year = "2008",
month = "7",
day = "1",
doi = "10.1111/j.1742-7843.2008.00238.x",
language = "English",
volume = "103",
pages = "48--54",
journal = "Basic and Clinical Pharmacology and Toxicology",
issn = "1742-7835",
publisher = "Wiley-Blackwell",
number = "1",

}

Licochalcone a inhibits the growth of colon carcinoma and attenuates cisplatin-induced toxicity without a loss of chemotherapeutic efficacy in mice. / Lee, Chang Ki; Son, Seung Hwa; Park, Kwang Kyun; Park, Jung Han Yoon; Lim, Soon Sung; Kim, Sook Hyang; Chung, WonYoon.

In: Basic and Clinical Pharmacology and Toxicology, Vol. 103, No. 1, 01.07.2008, p. 48-54.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Licochalcone a inhibits the growth of colon carcinoma and attenuates cisplatin-induced toxicity without a loss of chemotherapeutic efficacy in mice

AU - Lee, Chang Ki

AU - Son, Seung Hwa

AU - Park, Kwang Kyun

AU - Park, Jung Han Yoon

AU - Lim, Soon Sung

AU - Kim, Sook Hyang

AU - Chung, WonYoon

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Although chemotherapy has an important function in the treatment of most solid tumours, its clinical applications are limited by severe side effects such as nephrotoxicity, hepatotoxicity, ototoxicity and neurotoxicity. Recently, a growing amount of attention has been focused on the investigation of the effects of chemopreventive agents on the inhibition of cancer cell growth and toxicity in combination with chemotherapeutics. The aim of this study was to determine whether licochalcone A (LCA) has the potential to serve as a beneficial supplement during cisplatin chemotherapy. We found that the administration of LCA alone significantly inhibited the size of the solid tumours in CT-26 cell-inoculated Balb/c mice, without any detectable induction of nephrotoxicity, hepatotoxicity and oxidative stress. LCA also suppressed cell proliferation by reducing DNA synthesis of CT-26 murine colon cancer cells in a dose-dependent manner. LCA did not affect the therapeutic efficacy of cisplatin. Furthermore, LCA inhibited the cisplatin-induced kidney damage characterized by increases in the serum creatinine and blood urea nitrogen, as well as the cisplatin-induced liver damage characterized by increases in the serum alanine aminotransferase and aspartate aminotransferase. The repeated oral administration of LCA prior to cisplatin treatment exerted a preventive effect on the cisplatin-mediated increases in the serum nitric oxide and the tissue lipid peroxidation levels, and recovered the depleted reduced glutathione levels in the tissues. These results suggest that supplementation with LCA may be beneficial in counteracting the side effects of cisplatin therapy in cancer patients.

AB - Although chemotherapy has an important function in the treatment of most solid tumours, its clinical applications are limited by severe side effects such as nephrotoxicity, hepatotoxicity, ototoxicity and neurotoxicity. Recently, a growing amount of attention has been focused on the investigation of the effects of chemopreventive agents on the inhibition of cancer cell growth and toxicity in combination with chemotherapeutics. The aim of this study was to determine whether licochalcone A (LCA) has the potential to serve as a beneficial supplement during cisplatin chemotherapy. We found that the administration of LCA alone significantly inhibited the size of the solid tumours in CT-26 cell-inoculated Balb/c mice, without any detectable induction of nephrotoxicity, hepatotoxicity and oxidative stress. LCA also suppressed cell proliferation by reducing DNA synthesis of CT-26 murine colon cancer cells in a dose-dependent manner. LCA did not affect the therapeutic efficacy of cisplatin. Furthermore, LCA inhibited the cisplatin-induced kidney damage characterized by increases in the serum creatinine and blood urea nitrogen, as well as the cisplatin-induced liver damage characterized by increases in the serum alanine aminotransferase and aspartate aminotransferase. The repeated oral administration of LCA prior to cisplatin treatment exerted a preventive effect on the cisplatin-mediated increases in the serum nitric oxide and the tissue lipid peroxidation levels, and recovered the depleted reduced glutathione levels in the tissues. These results suggest that supplementation with LCA may be beneficial in counteracting the side effects of cisplatin therapy in cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=45749128172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45749128172&partnerID=8YFLogxK

U2 - 10.1111/j.1742-7843.2008.00238.x

DO - 10.1111/j.1742-7843.2008.00238.x

M3 - Article

VL - 103

SP - 48

EP - 54

JO - Basic and Clinical Pharmacology and Toxicology

JF - Basic and Clinical Pharmacology and Toxicology

SN - 1742-7835

IS - 1

ER -